Compare · ABT vs PLYX
ABT vs PLYX
Side-by-side comparison of Abbott Laboratories (ABT) and Polaryx Therapeutics Inc. (PLYX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and PLYX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $158.72B, about 691.2x PLYX ($229.6M).
- Over the past year, ABT is down 29.7% and PLYX is down 86.0% - ABT leads by 56.3 points.
- ABT has been more active in the news (8 items in the past 4 weeks vs 3 for PLYX).
- ABT has more recent analyst coverage (25 ratings vs 1 for PLYX).
- Company
- Abbott Laboratories
- Polaryx Therapeutics Inc.
- Price
- $91.15-1.41%
- $4.86-7.69%
- Market cap
- $158.72B
- $229.6M
- 1M return
- -13.05%
- -23.52%
- 1Y return
- -29.66%
- -85.99%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 8
- 3
- Recent ratings
- 25
- 1
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- Abbott showcases strength of its technologies to address abnormal heart rhythms with late-breaking clinical data at Heart Rhythm Society 2026
- SEC Form S-8 filed by Abbott Laboratories
- Abbott Labs downgraded by Daiwa Securities with a new price target
- Abbott Laboratories filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- New data at AACR 2026 demonstrate advancements in Cancerguard® Multi-Cancer Early Detection Test
- Abbott Laboratories filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences
- New survey finds most Americans believe chronic diseases are preventable, but only 1 in 4 feel confident in how to care for their health
- SEC Form 4 filed by Stratton John G
- SEC Form 4 filed by Roman Michael F
Latest PLYX
- Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference
- Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial
- Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care
- Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference
- Polaryx Therapeutics Receives FDA Fast Track Designation for PLX‑200 for Late‑Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease)
- Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events
- Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders
- Maxim Group initiated coverage on Polaryx Therapeutics with a new price target
- Chief Financial Officer Landis G. Michael bought $7,991 worth of shares (2,867 units at $2.79), increasing direct ownership by 1% to 228,225 units (SEC Form 4)
- Polaryx Therapeutics Selects Contract Research Organization for SOTERIA Phase 2 Basket Trial